Plain-English translation of NCT02573636 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →This research study is looking at two specific genetic markers (TMPRSS2-ERG gene fusion and PTEN) found in prostate cancer cells to see if they can predict how well hormone therapy will work for you. Researchers believe that understanding these genetic patterns may help doctors identify which patients are most likely to benefit from standard hormone treatment and which patients might need additional therapies.
Some men with advanced prostate cancer respond well to hormone therapy, while others do not. By identifying genetic markers that predict treatment response, doctors hope to personalize treatment plans and help patients avoid ineffective therapies or get additional treatment sooner when needed.
You likely qualify if…
You likely don't qualify if…
You will receive standard hormone therapy (LHRH agonist) as your primary treatment. Your doctors will monitor your PSA levels and disease progression over three years, and may add additional therapies or radiation if needed based on your response. Researchers will analyze genetic markers from your cancer tissue to determine if they can predict how well the treatment works for you and whether your cancer will progress.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Canada